These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 21456069)
21. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related]
22. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Pang S Cancer Gene Ther; 2000 Jul; 7(7):991-6. PubMed ID: 10917201 [TBL] [Abstract][Full Text] [Related]
23. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430 [TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related]
25. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Liu B; Lee KW; Li H; Ma L; Lin GL; Chandraratna RA; Cohen P Clin Cancer Res; 2005 Jul; 11(13):4851-6. PubMed ID: 16000583 [TBL] [Abstract][Full Text] [Related]
26. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464 [TBL] [Abstract][Full Text] [Related]
31. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice]. Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439 [TBL] [Abstract][Full Text] [Related]
32. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654 [TBL] [Abstract][Full Text] [Related]
33. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976 [TBL] [Abstract][Full Text] [Related]
35. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031 [TBL] [Abstract][Full Text] [Related]
36. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546 [TBL] [Abstract][Full Text] [Related]
37. Preclinical antitumor activity of the oral platinum analog satraplatin. Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592 [TBL] [Abstract][Full Text] [Related]
38. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905 [TBL] [Abstract][Full Text] [Related]
39. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter. Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029 [TBL] [Abstract][Full Text] [Related]
40. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways. Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]